{"id":702495,"date":"2022-10-28T07:55:04","date_gmt":"2022-10-28T11:55:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/"},"modified":"2022-10-28T07:55:04","modified_gmt":"2022-10-28T11:55:04","slug":"altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/","title":{"rendered":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">GAITHERSBURG, Md., Oct.  28, 2022  (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>American Heart Association Scientific Sessions 2022, Chicago, IL<br \/><\/strong>Saturday, November 5, 2022<br \/><em>Poster Presentation at 11:00 am Central Time<br \/><\/em>Title:\u00a0<em>Effect of Pemvidutide (ALT-801), a Novel GLP-1\/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators<br \/><\/em>Lead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women\u2019s Hospital<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>American Association for the Study of Liver Disease, The Liver Meeting<sup>\u00ae<\/sup><\/strong><br \/>\n          <strong>, Washington, DC<br \/><\/strong>Monday, November 7, 2022<br \/><em>Poster Presentation at 1:00 pm Eastern Time<br \/><\/em>Title: <em>Effects of a Balanced GLP-1\/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients with Non-alcoholic Fatty Liver Disease<br \/><\/em>Lead Author: Stephen A. Harrison, MD, Medical Director, Pinnacle Research<\/li>\n<\/ul>\n<p align=\"justify\">A copy of the presentation materials will be accessible on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-9Ks4v_GNL53l9F7sOpYXWMUkOG90setl0NrY8_D7_K3ED9AunloQNL_fBqHozDraeUPAowg1iQSpEiaBFdZzqcZWHfr7NuB9-F1PXzmwSyWVGMOjhbmZml2IMNrUjpT\" rel=\"nofollow noopener\" target=\"_blank\">Events<\/a> section of the Altimmune website.<\/p>\n<p align=\"justify\">\n        <strong>About Altimmune<br \/><\/strong>Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company\u2019s lead product candidate, pemvidutide, is a GLP-1\/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is developing HepTcell\u2122, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z8d-t5ToOsL3XONhXHiJ2eID277hSgXRrOCwMq1Ab1wpgqxG2DPvhDqaoyGzhcSNth0DF5L-uRNkCMfRtI06NA==\" rel=\"nofollow noopener\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p>\n        <strong>Follow @Altimmune, Inc. on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C4Am-rZRKY2smz29uVKET5yha-PCyMzu_XQdZlGSLsgOIpXAF50GQNtotshJyQa2PPXK0l1S579OZz8c8GORncfT0j9r041om7GMhUnFQd0=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>LinkedIn<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>\n        <strong>Follow @AltimmuneInc on <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mAilEBKonAAPIHfNt6bOOopogNnyosVOOSEfGYURGDBUI4YkIi3g7sybYM8cmOJ1J8HbkqzJUn0kERPyP5P5SQ==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>Twitter<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Altimmune Investor &amp; Media Contact:<\/strong>\n      <\/p>\n<p>Richard Eisenstadt<br \/>Chief Financial Officer<br \/>Phone: 240-654-1450<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yJaGn1OIwKxVFuM-gEKr9geM3xGNximJRPCLjGJ9kbKnRTMQT4RfA-l63nx3FQodM-0MqaLNC2lM3YQ4VtucNQuvB1_suKryzNa0DWx-zPk=\" rel=\"nofollow noopener\" target=\"_blank\">reisenstadt@altimmune.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2Y5ZTUyOGUtNGQ1Yy00Y2Y5LTg1ZjgtMTI1ZWVhM2E3YWE1LTEwMjIyNDk=\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago, ILSaturday, November 5, 2022Poster Presentation at 11:00 am Central TimeTitle:\u00a0Effect of Pemvidutide (ALT-801), a Novel GLP-1\/Glucagon Dual Receptor Agonist, on Pathogenic Lipid MediatorsLead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women\u2019s Hospital American Association for the Study of Liver Disease, The Liver Meeting\u00ae , Washington, DCMonday, November 7, 2022Poster Presentation at 1:00 pm Eastern TimeTitle: Effects of a Balanced GLP-1\/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-702495","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago, ILSaturday, November 5, 2022Poster Presentation at 11:00 am Central TimeTitle:\u00a0Effect of Pemvidutide (ALT-801), a Novel GLP-1\/Glucagon Dual Receptor Agonist, on Pathogenic Lipid MediatorsLead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women\u2019s Hospital American Association for the Study of Liver Disease, The Liver Meeting\u00ae , Washington, DCMonday, November 7, 2022Poster Presentation at 1:00 pm Eastern TimeTitle: Effects of a Balanced GLP-1\/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, &hellip; Continue reading &quot;Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-28T11:55:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae\",\"datePublished\":\"2022-10-28T11:55:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/\"},\"wordCount\":273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/\",\"name\":\"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=\",\"datePublished\":\"2022-10-28T11:55:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae - Market Newsdesk","og_description":"GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022: American Heart Association Scientific Sessions 2022, Chicago, ILSaturday, November 5, 2022Poster Presentation at 11:00 am Central TimeTitle:\u00a0Effect of Pemvidutide (ALT-801), a Novel GLP-1\/Glucagon Dual Receptor Agonist, on Pathogenic Lipid MediatorsLead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women\u2019s Hospital American Association for the Study of Liver Disease, The Liver Meeting\u00ae , Washington, DCMonday, November 7, 2022Poster Presentation at 1:00 pm Eastern TimeTitle: Effects of a Balanced GLP-1\/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, &hellip; Continue reading \"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-28T11:55:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae","datePublished":"2022-10-28T11:55:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/"},"wordCount":273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/","name":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=","datePublished":"2022-10-28T11:55:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4NDA2NiM1MjI5MjczIzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-present-pemvidutide-clinical-data-at-the-upcoming-aha-scientific-sessions-and-aasld-the-liver-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/702495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=702495"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/702495\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=702495"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=702495"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=702495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}